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ABSTRACT
Objective: This study was performed to formulate a floating tablet using hydrophobic glyceryl behenate (GB) and hydrophilic hydroxypropyl 
methylcellulose polymers, optimization of the same for retention in stomach and sustained drug delivery over a period of 20 h from upper 
gastrointestinal tract so as to increase its oral bioavailability.
Methods: Granules of GB with the metoprolol succinate (MS) was formulated and compressed with the other ingredients to formulate a floating 
tablet. Physiochemical parameters of an optimized formulation along with its in vitro buoyancy study, dissolution study, in vivo studies in rabbit, and 
stability studies were performed.
Results: Differential scanning calorimetry data show no interaction between polymers and the drug MS. A 32 factorial design was applied for 
optimization purpose, and from ANOVA and surface response plot the best formulation (F3) was obtained. In vitro dissolution study shows sustained 
drug release for 20 h for all the formulations and in vivo studies using rabbit model show increased bioavailability of an optimized formulation F3 as 
compared to the marketed sustained release formulation of MS (25 mg). Stability study shows no comparable differences in physical parameters and 
the drug release of initial formulation and the one which is kept for accelerated stability testing.
Conclusion: Hence, we can conclude that a floating tablet containing a combination of hydrophilic and hydrophobic polymers can be used for gastric 
retention for more than 20 h which will increase the oral bioavailability of MS.
Keywords: Gastroretentive formulation, Metoprolol succinate, Glyceryl behenate, Improved bioavailability.
INTRODUCTION
Gastroretentive drug delivery system is a type of sustained drug 
delivery system in which dosage form is retained in the upper 
gastrointestinal region, used mainly for drugs which are absorbed 
from the stomach or which are degraded in colon, so as to improve 
its therapeutic effects and patient compliance. Poor bioavailability of 
many drugs is due to its unfavorable physicochemical characteristics 
or absorption in a well-defined part of the gastrointestinal tract 
referred as “absorption window” [1]. According to biopharmaceutics 
classification system, metoprolol succinate (MS) is classified under 
Class  I: With high  solubility,  high permeability  [2]  and used  as  a  β1-
selective adrenoreceptor blocking agent for treatment of hypertension 
and coronary heart diseases. Its poor bioavailability of <50% is due 
to rapid first-pass metabolism and degradation in the colon [3,4]. The 
half-life of it is 3–4 h [3]; therefore, multiple doses are required to 
maintain constant plasma levels of the drug, which can be achieved by 
sustaining the drug release for desired therapeutic effects in the upper 
gastrointestinal region to improve its oral bioavailability.
Many attempts have been taken to study sustained release (SR) matrix 
tablets of MS, using different polymer combinations and fillers.
Sabahuddin et al. studied the effect of hydroxypropyl methylcellulose 
(HPMC) and ethylcellulose on drug release of MS and oral bioavailability 
of it in rabbits by formulating SR matrix tablets [5].
Here, we used a combination of hydrophilic HPMC and hydrophobic 
glyceryl behenate (GB) with other fillers to formulate a floating tablet 
of MS which will release the drug for more than 20 h from the stomach 
and thereby improves the oral bioavailability of the formulation.
The objective of this study is to develop an optimized floating tablet 
of MS and to understand the   drug release from such systems with 
hydrophilic (HPMC) and hydrophobic (Glyceryl behenate) polymers, 
optimization of formulation by design expert software, stability testing 
of an optimized formulation, evaluation of an optimized formulation 




MS was obtained as a gift sample from Wockhardt Limited, Aurangabad, 
India. HPMC K100M, GB, mannitol, polyvinylpyrrolidone (PVP), sodium 
bicarbonate (NaHCO3), magnesium stearate, and MCC were obtained 
as a gift sample from Colorcon, Pvt., Ltd., Goa, India. All other solvents 
and reagents were purchased from Thermo Fischer scientific Pvt., Ltd., 
Mumbai, India, and were of analytical grade.
Method
Calibration curve for MS was obtained in 0.1 N HCL. Between the linearity 
range of 2–10 µg/ml and correlation coefficient (r2) of determination 
were obtained at 222 nm (R=0.9985), using an ultraviolet (UV)-visible 
spectrophotometer (Shimadzu UV-1800, Japan). The calibration curve 
in 0.1N HCl was used for dissolution studies [6].
Tablet formulation
Here we have made a combination of hydrophilic and hydrophobic 
polymers, to do so the granules of glyceryl behenate and mannitol with 
the drug was made by melting glyceryl behenate and adding MS and 
mannitol to the molten mass of glyceryl behenate which was  allowed 
to solidify to form granules. These granules were passed from sieve 
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i8.25979
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of appropriate mesh size, other polymers and fillers such as HPMC 
K100M, PVP, MCC except lubricant, and gas-generating agent were 
dry mixed and added to the above-prepared granules, finally, NaHCO3 
and magnesium stearate were added to the mixture just before 
compression. Mixing continued for another 5 min, and finally, the mixed 
powder blend was compressed using punches of 8.5 mm on single 
rotary compression machine (Make: Rimek, Model: R and D model), to 
produce the desired tablets. The hardness of the tablet was adjusted at 
3–4 kg/cm2 using a Monsanto hardness tester. The effects of selected 
variables on drug release were studied using 32 factorial designs, in 
which the effect of the two variables, i.e., GB and HPMC on percent drug 
release was observed. Other variables such as amount of MS, NaHCO3, 
PVP, MCC, and magnesium stearate were kept constant. The three-level 
set includes lower level (−1), middle level (0), and upper level (+1).
Formulation design: Formulation design study is important for selection 
of appropriate excipients for preparing tablets.
Full factorial design
A 32 randomized full factorial design was constructed to study. In this 
design, two factors were evaluated, each at 3 levels and experimental 
trials were performed at all 9 possible combinations which are shown in 
Table 1. The amount of HPMC K100M (X1) and GB (X2) was selected as 
independent variables. The dependent variable chosen was percentage 
drug release at 20th h [7].
All other ingredients, such as MS=23.5 mg, mannitol= 25 mg, 
NaHCO3=15 mg, MCC=60 mg, PVP=15 mg, and magnesium 
stearate=2.5 mg were kept constant in all the formulations.
Determination of pre-compression and post-compression 
parameters
Tap density of granules was determined by a measuring cylinder. Bulk 
density of granules, percent compressibility (Carr’s index), and angle of 
repose was determined.
The tablets were stored at least for 7 days at room temperature 
before characterization. 10 samples of each formulation were chosen 
randomly for conducting each test.
The thickness of tablet was determined using Vernier Caliper. Three 
tablets from each formula were used, and average values were 
calculated as±standard deviation (SD) [8].
Hardness test
The hardness of the tablet (Kg/cm2) was determined using hardness 
tester. In which three tablets from each formula were tested and the 
average reading±SD was recorded [9].
The weight variation of the prepared floating tablet was determined by 
weighing 20 prepared floating tablets individually and then calculated 
its average weight and comparing the weight of each tablet to the 
average weight [10].
Friability test
Weight 20 tablets and placed them in the friabilator and the device 
was rotated at 25 rpm for (4 min). After revolutions, the tablets then 
de-dusted and weighed again. The acceptable percentage weight loss 
or percentage  friability should be ˂1%. The percentage  friability was 
determined using the following formula:[11].
% Friability=(initial weight−final weight/initial weight) ∗100
Drug content
Ten tablets of an equal weight of the prepared tablets were selected 
and powdered using mortar and pestle. Then, powder equivalent to the 
average weight of the prepared tablet was weighed and dissolved in HCl 
solution (pH1.2).
The solution was filtered and about 1 ml of the filtrate was appropriately 
diluted and analyzed for MS content using UV spectrophotometer 
at 222 nm as the wavelength of maximum absorption [12]. Data are 
tabulated in Tables 2 and 3.
In vitro buoyancy studies
In a beaker of 100 ml, 0.1N HCL was taken, and a formulation was 
dropped in it and observed for floating lag time (FLT), total floating time 
(TFT), and for tablet’s matrix integrity (MI).
The test was done by placing the tablet in 100 ml beaker containing HCl 
solution (pH1.2), and the temperature of the medium is maintained at 
37±0.5°C. The time between the introduction of tablet and its buoyancy 
in HCl solution (pH1.2) is the FLT, while the time during which the 
tablet remains buoyant in the solution is the TFT [13].
In vitro dissolution studies
It was carried out in a dissolution test apparatus Electrolab TDT-06L 
for more than 20 h, according to united state pharmacopeia [14]. Each 
vessel containing about 500 ml of 0.1N HCL was taken, and the paddle 
apparatus with a speed of 75 rpm was used, while the temperature 
was kept constant at 37°C±0.5°C. At every time interval, 5 ml of 
media was withdrawn, filtered, diluted, and measured by UV-visible 
spectrophotometer at 222 nm. Furthermore, 5 ml of 0.1N HCL was 
replaced into the vessel to keep the volume constant. The dissolution 
was taken in triplicate for each formulation and percentage release 
was calculated using PCP diss. Software. ANOVA was performed for 
optimization purpose.
Differential scanning calorimetry (DSC)
The DSC was done for MS, GB, and formulation F3, using a SHIMADZU 
DSC-60 plus DSC. The system was calibrated with a high purity sample 
of Indium. MS was scanned at the temperature rate of 10°C/min over 
a range of 50–250°C under a nitrogen atmosphere using aluminum 
pans. Peak transitions and enthalpy of fusion were determined for 
the samples using TA60 integration software. Curves for them are 
interpreted below.
Table 1: Development of floating tablets prepared by 32 factorial design and their response
Formula code Variables Drug release at 20th hr
X1—amount of HPMC K100M (mg) X2—amount of GB (mg) (%)
F1 57.5 22.5 82.80
F2 57.5 20 83.1
F3 57.5 17.5 85.9
F4 55 22.5 89.9
F5 55 20 88.20
F6 55 17.5 91.33
F7 52.5 22.5 91.47
F8 52.5 20 92.77
F9 52.5 17.5 93.99
HPMC: Hydroxypropyl methylcellulose
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Accelerated stability studies
Accelerated stability study was carried out for 6 months according to 
international conference on Harmonization (ICH) guidelines- Q1A(R) 
stability testing of new drug substance and finished products. (Now 
referred to as the parent guideline) to propose a retest period or 
shelf life, under specified conditions of temperature and humidity 
of around 40°C±2°C/75% RH±5% RH for 6 months. To find out the 
quality of finished product that is the optimized formulation F3 
under a variety of conditions. For this, the tablets were packed in 
an aluminum packaging and kept in a stability chamber. At the end 
of every month, the samples were withdrawn and evaluated for 
hardness, drug content, floating characteristics (FLT and MI), and 
percentage drug release at 20th h.
Biopharmaceutical evaluation
This study was done to determine the bioavailability of MS in a rabbit 
model and was performed according to the guidelines of CPCSEA, 
ministry of social justice and empowerment, Government of India. The 
pro forma B having protocols for animal study was approved by the 
Institutional Animal Ethical Committee, Y.B Chavan College of Pharmacy, 
Aurangabad, Registration no: 844/ac/04/CPCSEA. For this six healthy 
male rabbits were selected and divided into two groups of three each, 
labeled as A and B. Group A was fed with optimized formulation of our 
study and Group B was fed with the marketed formulation of MS (Met-
XL 25 mg tab). Before giving the dose, the animals were acclimatized for 
1 week in the animal house and taken care of their diet. Humidity and 
temperature of the room were controlled. After giving the dose of MS 
tablets to each group, blood sample was removed from the marginal ear 
of each animal into a pre added K3 EDTA Accuvet at a predetermined 
intervals of time, i.e., m at 0h (before giving dose) then at 1, 2, 3, 4, 6, 
8, 10, 12, 16, 18, 20, and 24, minimum 2 ml of blood was collected at 
each interval of time and was centrifuged immediately for 10 min at 
2500 rpm to separate plasma from it, this plasma was collected into 
another set of tubes and was frozen until assayed.
For analysis of MS concentration in blood plasma of rabbits, we used 
HPLC method. For this standard, HPLC method was developed by 
preparing a mixture of phosphate buffer and acetonitrile in a ratio of 
80:20, respectively, as a mobile phase and was used at a flow rate of 
1 ml/min. The linearity range was found between 5 and 100 ng/ml 
and the correlation coefficient was found to be 0.9991. Before analysis 
of plasma by HPLC method, the plasma was filtered through 0.25 µm 
membrane filter and 0.2 ml of filtered plasma was taken and diluted 
Table 2: Characterization of granules of MS
Formulation 
code






F1 0.56 17.54±0.4 29±0.6
F2 0.51 18.22±0.6 29±0.5
F3 0.47 20.15±0.5 30±0.9
F4 0.51 18.11±0.2 27±1.1
F5 0.49 17.92±0.5 29±0.8
F6 0.51 18.17±0.6 28±0.6
F7 0.47 20.21±0.5 27±0.7
F8 0.45 17.12±0.4 26±0.9
F9 0.44 16.45±0.6 28±0.8
MS: Metoprolol succinate

















F1 2.1±0.01 216.2±0.9 4.12±0.11 98.45±0.66 0.58 3.5 >18
F2 2.2±0.02 212.6±0.8 4.16±0.35 99.21±0.36 0.69 3 >20
F3 1.9±0.03 213.1±0.5 3.55±0.55 100.14±0.86 0.87 3.5 >19
F4 1.8±0.01 211.9±0.6 3.89±0.12 98.33±0.98 0.65 3.5 >20
F5 2.3±0.02 217.6±0.8 3.45±1.22 102.36±0.36 0.35 3 >19
F6 2.4±0.03 215.1±0.8 3.48±0.045 98.96±0.25 0.64 3.5 >20
F7 2.1±0.01 216.2±0.5 3.89±1.54 99.12±0.65 0.54 4 >18
F8 2.2±0.02 218.3±0.6 3.66±0.56 101.32±0.86 0.46 3.5 >17
F9 2.1±0.03 215.8±0.9 3.22±0.66 100.24±0.84 0.84 3 >18




Asian J Pharm Clin Res, Vol 11, Issue 8, 2018, 79-84
 Fatema and Shahi 
with 1 ml of acetonitrile and again centrifuged to obtain a supernatant. 
This supernatant was evaporated under nitrogen, and the residue was 
mixed with 0.3 ml of HPLC mobile phase. Now, this is the final sample 
to be injected into the column of HPLC (XDB-C18, 150 mm×4.6 mm, and 
5 µm) with UV detector at a wavelength of 223 nm.
Data obtained from this study were plotted as plasma concentration 
versus time and bioavailability was determined from AUC.
RESULTS AND DISCUSSION
Selection of polymers
As we chose to use a combination of hydrophilic and hydrophobic 
polymers, various grades of HPMC were tested for its viscosity, as lower 
grades of HPMC disintegrates faster because of its lower viscosity, 
which is again due to less water sorption to relax its polymeric chain.
Therefore, higher viscosity grades of HPMC, i.e., HPMC K100M were 
preferred for our study. Further, GB was found to be used as a matrix 
forming agent for the controlled release of water-soluble drugs. It has 
also been investigated for use in the preparation of sustained-release 
tablets [15–20]. Hence, it was selected in our study.
Formulation and optimization of floating tablets of MS
As GB is waxy in nature it was melted in a porcelain dish and mixed with 
a diluent that is mannitol because granulations containing mannitol are 
easily dried [21]. Then, this mass was passed through sieve no.18, and 
the granules were dried for some time at room temperature. To these 
granules were added some other excipients such as HPMC K100M, PVP, 
and MCC and were dry mixed in a poly bag for 10 min. Then, just before 
compression NaHCO3 and magnesium stearate were added to the above 
mixture and finally compressed in a tablet compression machine using 
punches of 8.5 mm. (Make: Rimek, Model: R and D model), to produce 
the desired tablets.
Various trial batches were prepared using a different concentration of 
selected polymers to obtain an optimized tablet of around 3–4 kg/cm2 
hardness and which can retard the drug release for 20 h in acidic media 
that is under floating conditions. Finally, a formulation containing 20 mg 
of GB and 55 mg of HPMC K100M was found to give the desired results 
with 15 mg of NaHCO3. Hence, a 32 factorial design was applied to this 
formulation, where X1-HPMC and X2-G.B were selected as independent 
variables, and its effect was studied on drug release at 20th h. Pre-
compression and post-compression parameters are tabulated in Table 2.
In vitro buoyancy studies
After fixing the amount of polymers to be taken for retardation of 
drug release for almost more than 20 h in the stomach, the amount of 
NaHCO3 was taken so as to achieve minimum FLT and maximum floating 
duration or time. It was found that 15 mg of NaHCO3 was sufficient to 
give the desired results.
Most of the prepared floating tablet formulas had acceptable FLT and 
TFT due to the presence of the gas generating agent within the formulas, 
when this agent become in contact with the acidic dissolution media 
(HCl solution, pH1.2) it generates carbon dioxide gas which entrapped 
within the gelling layer of the hydrophilic polymer. Furthermore, due to 
the swelling of the hydrocolloid particle on the surface after exposure to 
the aqueous gastric fluids, this sequentially results in an increase bulk 
volume and provides buoyancy to the floating tablet dosage forms [22].
In vitro drug release
Percent drug release for all nine formulations was determined and 
plotted against time (h), from Fig. 1 it was concluded. That F1 showed 
a very less release of 82.8% at 20 h with slight increase in percentage 
release from F2 to F3, maybe because of high percentage of both the 
polymers in F1 and as the concentration of G.B decreases percentage 
drug release increases to a very low extent which, in turn, shows that 
a decrease in concentration of GB has not much effect on drug release 
of the formulations. Again there is a significant increase in percentage 
drug release of F4, F5, and F6 formulations because of a decrease in 
concentration of HPMC K100M which plays a major role in drug release 
mechanism of our formulations and finally, we can conclude that as the 
concentration of HPMC K100M decreases the percentage drug release 
increases to a significant amount.
DSC
The DSC thermogram of MS indicates a sharp peak at 140.31°C which 
corresponds to the melting point of MS (Fig. 2). The thermogram of 
F3 formulation also exhibited the characteristic endotherm of MS, 
indicating the crystalline state of the drug and no interaction with other 
excipients. In the thermogram of F3 formulation (Fig. 3), the endotherm 
observed at 73.09°C corresponds to melting of GB, while the endotherm 
at 166.36°C is attributed to degradation of NaHCO3.
ANOVA for response surface linear model
The Table 4 of analysis of variance shows that the Model F-value of 
46.93 implies the model is significant. Values of “p> F”<0.0500 indicate 
model terms are significant.
Table 4: Analysis of variance table
Source Sum of squares df Mean square F value p value p>F
Model 125 2 62.4 46.9 <0.0001 Significant
A-HPMC K100M 116 1 116. 87.6 <0.0001
B-GB 8.28 1 8.28 6.24 0.0371
Residual 10.6 8 1.33
Lack of fit 10.6 6 1.77
Pure error 0.000 2 0.000
Cor total 135 10
HPMC: Hydroxypropyl methylcellulose, GB: Glyceryl behenate
Table 5: Pharmacokinetic parameters and bioavailability of F3 
formulation and marketed SR formulation







F3 formulation 4.0±0.21 90±24 1576.08
SR: Sustained release
Fig. 2: Differential scanning calorimetry thermogram of 
metoprolol succinate pure drug
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R1 is a response (that is, percent drug release at 20 h); negative sign on 
both the independent variable indicates that as the percentage of them 
decreases, drug release increases. Further, higher magnitude of A shows 
that polymer A has a greater impact on drug release. That means a small 
change in concentration of polymer A has a significantly large impact 
on percentage drug release. Hence, we can conclude that polymer A has 
greater impact as compared to variable B in our formulation study.
Response surface plot for release in 20 h Fig. 4 shows response surface 
plot.
Accelerated stability studies
Accelerated stability study was carried out for 6 months at a specified 
range of temperature and humidity of 40°C±2°C/75% RH±5%, 
respectively, as specified under ICH guidelines-Q1A(R) stability testing 
of new drug substance and finished products. A study carried out under 
such condition shows that the optimized formulation F3 is stable for 
6 months as there are negligible changes in some parameters such as 
hardness, drug content, floating characteristics FLT, and percentage 
drug release at 20thh.
Bioavailability study of floating tablet of MS
After in-vivo studies the analysis of plasma was carried out by HPLC. The 
data were obtained and plotted against time, i.e., plasma concentration 
versus time. This gives a curve shown in Fig. 5 from which various 
pharmacokinetic parameters were studied and reported below.
The extent of absorption gives an idea about bioavailability and is a 
characteristic of any formulation.
Here, we have compared the bioavailability of our optimized 
formulation with that of the marketed formulation. As the AUC of the 
studied formulations were significantly different, we can conclude 
that our optimized formulation has improved bioavailability than the 
marketed preparation. Thus, AUC can be used for comparative study of 
two formulations.
The Table 5 shows that Tmax, t1/2, and Cmax were slightly different for the 
two studied formulations.
CONCLUSION
From the experimental data and the results, we can conclude that a 
combination of hydrophilic and hydrophobic polymers can be used to 
formulate a floating tablet of MS which can release the drug for more 
than 20 h with improved bioavailability. Further, DSC analysis confirms 
no interaction between the polymers and drug. Accelerated stability 
study reveals that the formulation was stable for 6 months. Hence, we 
can conclude that the studied formulation could release the drug in the 
upper part of GIT for more than 20 h and has increased bioavailability 
as compared to the marketed preparation and is stable under specific 
Fig. 3: Differential scanning calorimetry thermogram of F3 
Formulation
Fig. 4: Response surface plot, showing the response of polymer 
composition on “drug release in 20 h” (Rel20th h) from floating 
tablet
Fig. 5: The plasma concentration versus time profile of F3 formulation and the marketed SR formulation
In this case, A and B are significant model terms. Values >0.1000 
indicate the model terms are not significant.
The “Pred R-squared” of 0.8557 is in reasonable agreement with the “Adj 
R-squared” of 0.9018; i.e., the difference is <0.2. “Adeq Precision” measures 
the signal to noise ratio. A ratio >4 is desirable. Our ratio of 18.540 indicates 
an adequate signal. This model can be used to navigate the design space.
Final equation in terms of coded factors
R1= 88.7–4.40 A-1.17B
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conditions of temperature and humidity. Successful in vivo studies 
encouraged for further study in human volunteers.
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